Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Esophageal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002711
- Testing
- chemotherapy, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Oral Mucositis, Oral Stomatitis
Ozone Therapy for Oral Mucositis in Patients Receiving Head and Neck Cancer Radio- and Chemotherapy
Oral mucositis is a frequent and painful side effect of radio- and chemotherapy, especially in patients with head and neck cancer.
- Conditions
- Oral Mucositis, Oral Stomatitis, Head and Neck Cancer Squamous Cell Carcinoma, Radiotherapy Induced Mucositis
- Trial name
- OZOMUC (NCT07199712)
- Testing
- Ozone Therapy (In-Office and Home-Based Treatment)
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Pavia
Esophageal Neoplasm, Esophageal Diseases
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer
- Conditions
- Esophageal Neoplasm, Esophageal Diseases, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04481100
- Testing
- itraconazole
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Hangzhou Cancer Hospital
Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
The purpose of the Phase I study is to see if it is safe to use X-ray photon radiation (XRT) and proton radiation (PT) before surgery in patients with recurrent head and neck squamous cell carcinoma (rHNSCC).
- Trial name
- NCT07213934
- Testing
- Proton therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Oropharyngeal Neoplasms
Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma.
The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.
- Trial name
- NCT00251381
- Testing
- Cetuximab
- Where
- 18 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Trial Form Support S.L.
Esophageal Carcinoma
Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer
Esophageal carcinoma is a lethal disease, causing more than 400,000 deaths annually worldwide. Primary surgery results in microscopically positive resection margins (R1) in 25% patients, and the 5-year overall survival(OS) for…
- Trial name
- NCT02527057
- Testing
- DW-MRI
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hunan Province Tumor Hospital
Esophageal Cancer
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.
This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the safety and effect of anti-PD-L1 antibody (ZKAB001) in neoadjuvant chemotherapy of esophageal squamous carcinoma in combination with…
- Trial name
- NCT04460066
- Testing
- anti-PD-L1 antibody, albumin bound paclitaxel, cisplatin
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Lee's Pharmaceutical Limited
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Cervical Squamous Cell Carcinoma
A Prospective Study of the Early Treatment of Recombinant Human Thrombopoietin for Chemoradiation Induced Thrombocytopenia in Cervical Squamous Cell Carcinoma Patient
To explore the early intervention timing of recombinant human thrombopoietin (rhTPO) for cancer treatment-induced thrombocytopenia (CTIT) in cervical squamous cell carcinoma (CSCC) patients during concurrent chemoradiotherapy.
- Trial name
- NCT07649395
- Testing
- rhTPO
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Mei Feng
Head and Neck Cancer
S9709, Laser Surgery Plus Radiation Therapy in Treating Patients With Early Stage Cancer of the Larynx
RATIONALE: Laser surgery for cancer of the larynx may have fewer side effects and improve recovery. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003040
- Testing
- laser surgery, radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 42 people
- Sponsor
- SWOG Cancer Research Network
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer.
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06532279
- Testing
- Best Practice, Biospecimen Collection, Cisplatin
- Where
- 153 sites in United States
- Volunteers
- 98 people
- Sponsor
- NRG Oncology
Head and Neck Squamous Cell Carcinoma
Ruxolitinib in Operable Head and Neck Cancer
The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery.
- Trial name
- NCT03153982
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Advanced Malignancies
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies.
- Trial name
- NCT05577182
- Testing
- INCA32459-101
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 46 people
- Sponsor
- Incyte Corporation
Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Primary Non-operated Squamous Cell Carcinoma of Oropharynx
Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.
The investigators hypothesize that treatment adaptation to biological and anatomical changes, occurring during treatment, can increase the chance of cure at minimized or equal radiation-induced toxicity in head and neck cancer…
- Conditions
- Primary Non-operated Squamous Cell Carcinoma of Oral Cavity, Primary Non-operated Squamous Cell Carcinoma of Oropharynx, Primary Non-operated Squamous Cell Carcinoma of Hypopharynx, Primary Non-operated Squamous Cell Carcinoma of Larynx
- Trial name
- C-ART-2 (NCT01341535)
- Testing
- Adaptive dose-painting-by-numbers, standard intensity-modulated radiotherapy (IMRT)
- Where
- 2 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab [89Zr panitumumab]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT05747625
- Testing
- Panitumumab, Zirconium Zr 89 Panitumumab, Positron Emission Tomography
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Eben Rosenthal
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma
- Trial name
- NCT06183268
- Testing
- Spot Delete
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Covenant Health Cancer Center
Squamous Cell Carcinoma of Head and Neck
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Subjects will receive treatment with nivolumab monotherapy at 240mg flat dose as a 30 minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death…
- Trial name
- NIVACTOR (NCT05802290)
- Testing
- Nivolumab 240 MG in 24 ML Injection
- Where
- 23 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Oropharyngeal Cancer, Head and Neck Cancer
Sexual Behavior in Head and Neck Cancer Patients
The goal of this behavioral research study is to learn if certain sexual behaviors increase the risk for developing head and neck cancers associated with a virus called human papillomavirus (HPV-16).
- Conditions
- Oropharyngeal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma
- Trial name
- NCT00662662
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Squamous Carcinoma
Neoadjuvant SBRT in Localized Advanced HNSCC
The response rate of HNSCC to immune checkpoint blockade was not satisfied. Improving the mPR rate of neoadjuvant immunotherapy through the combination with other treatment methods is an important way to further improve the…
- Trial name
- NCT06306846
- Testing
- SBRT+immunochemotherpy, Immunochemotherapy, cetuximab+immunochemotharpy
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Jiang Feng
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.